Modifications in the branched arms of a class of dual inhibitors OF HIV and EV71 replication expand their antiviral spectrum

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDSViral Infections, Non-HIV

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Antiviral Res.

Hu Y, Zhang J, Musharrafieh RG, Ma C, Hau R, Wang J

doi: 10.1016/

HIV / AIDS

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV

HIV Med.

Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM

doi: 10.1111/hiv.12833.

HIV / AIDS

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

Antivir Ther.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC, Swiss HIV Cohort Study

doi: 10.3851/IMP3310.

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

HIV / AIDS

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

Clin Infect Dis.

Deutschmann E, Bucher HC, Jaeckel S, Gibbons S, McAllister K, Scherrer AU, Braun DL, Cavassini M, Hachfeld A, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, Marzolini C, Swiss HIV Cohort Study.

doi: 10.1093/cid/ciaa918.

HIV / AIDS

No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy

HIV Med

Lajaunie R, Cuzin L, Palich R, Makinson A, Bani-Sadr F, Duvivier C, Arvieux C, Rey D, Poizot-Martin I, Delpierre C, Delobel P, Martin-Blondel G, And The Dat’AIDS study group.

doi: 10.1111/hiv.13168

HIV / AIDS

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers

Sci Rep.

Nyanhete TE, Frisbee AL, Bradley T, Faison WJ, Robins E, Payne T, Freel SA, Sawant S, Weinhold KJ, Wiehe K, Haynes BF, Ferrari G, Li QJ, Moody MA, Tomaras GD

doi: 10.1038/s41598-

HIV / AIDS

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study

AIDS.

Bouzidi KEL, Jose S, Phillips AN, Pozniak A, Ustianowski A, Gompels M, Winston A, Schaap A, Dunn DT, Sabin CA, UK CHIC Study.

doi: 10.1097/QAD.0000000000002603.

Related content

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021